...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)

【24h】

A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D)

机译：sEphB4-HSA在人体内的I期研究首次在晚期实体瘤患者中以最大耐受剂量（MTD）或推荐的II期剂量（RP2D）扩张

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2016年第null期|共1页
作者
El-Khoueiry A.; Gitlitz B.; Cole S.; Tsao-Wei D.; Goldkorn A.; Quinn D.; Lenz H. J.; Nieva J.; Dorff T.; Oswald M.; Berg J.; Menendez X.; Karakozian K.; Krasnoperov V.; Liu R.; Thomas J.; Groshen S.; Gill P.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) [J] . El-Khoueiry A., Gitlitz B., Cole S., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2016,第Null期

机译：sEphB4-HSA在人体内的I期研究首次在晚期实体瘤患者中以最大耐受剂量（MTD）或推荐的II期剂量（RP2D）扩张
2. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors (vol 36, pg 3298, 2018) [J] . Strickler J. H., Weekes C. D., Nemunaitis J. Journal of Clinical Oncology . 2019,第3期

机译：患有先进实体瘤的患者的靶向C-MET的抗体 - 药物缀合物的抗体 - 药物缀合物的抗体 - 药物缀合物的第一阶段I，剂量 - 升级和延伸研究（Vol 36，PG 3298,2018）
3. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors [J] . Strickler John H., Weekes Colin D., Nemunaitis John, Journal of Clinical Oncology . 2018,第33期

机译：患有先进实体肿瘤的患者的靶向C-Met的抗体 - 药物缀合物的抗体 - 药物缀合物的一阶段I，剂量升级和延伸研究。
4. SAFETY EVALUATION OF COMBINATION DOXORUBICIN AND TOCERANIB PHOSPHATE (PALLADIA(R)) IN TUMOR BEARING DOGS: A PHASE I DOSE FINDING STUDY (VCS Award Winner) [C] . Pellin MA, Wouda RM, Robinson K, Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：肿瘤携带犬组合Doxorubicin和Toceranib磷酸盐（Palladia（R））的安全评估：I阶段查找研究（VCS奖获得者）
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. Safety tolerability pharmacokinetics and pharmacodynamics of the afucosylated humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors [O] . Kohei Shitara, Taroh Satoh, Satoru Iwasa, 2019

机译：无岩藻糖基化的人源化抗EPHA2抗体DS-8895a的安全性耐受性药代动力学和药效学：在患有晚期实体瘤的患者中进行的人体内第一阶段I剂量递增和剂量扩展研究
7. Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation [O] . Wood W.A., Walko C.M., Rao K.V., 2009

机译：一，以药代动力学为基础的剂量I期，确定每天连续定量（CI）白消安（BU）与固定剂量氟达拉滨（FLU）静脉连续输注（CI）白消安（BU）的最大耐受剂量（MTD）为每天7603 Umol * Min / Hr的AUC异基因干细胞移植后血液系统恶性肿瘤患者（PTS）的研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号